Skip to main content
NVCT
NASDAQ Life Sciences

Nuvectis Licenses Two Clinical-Stage Compounds, NXP100 Shows Superiority to Soliris in Phase 3 PNH Trial

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$14.2
Mkt Cap
$366.583M
52W Low
$5.55
52W High
$14.16
52W Position info
156% above low
Off High info
at 52W high
Rel. Volume info
3.7× avg
Market data snapshot near publication time

NVCT has more than doubled off its 52-week low of $5.55 on elevated volume (3.7× avg).

Summary

Nuvectis Pharma secured exclusive ex-China rights to two clinical-stage compounds, NXP100 and NXP200, from Haisco Pharmaceutical Group. NXP100, a Factor B inhibitor, demonstrated superiority to Soliris in a Phase 3 study for Paroxysmal Nocturnal Hemoglobinuria (PNH), with two MAAs already submitted in China. This significantly expands Nuvectis' pipeline with potentially best-in-class assets, adding a late-stage program with strong clinical validation. The deal follows Nuvectis' Q1 report of a net loss and cash burn, making this pipeline expansion critical for future growth. The company is hosting a conference call today at 8:30 AM ET to discuss the new products.

At the time of this announcement, NVCT was trading at $14.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $366.6M. The 52-week trading range was $5.55 to $14.16. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

NVCT - Latest Insights

NVCT
Nov 05, 2026, 3:00 AM EST
Source: Wiseek News
Importance Score:
8
Price at Filing: $19.42
Real-time Price: $20.40 info
Change: +$0.980 (+5%) info
Market Cap: $682.276M info
NVCT
Nov 04, 2026, 8:07 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $19.34
Real-time Price: $20.40 info
Change: +$1.06 (+5%) info
Market Cap: $682.276M info
NVCT
Nov 04, 2026, 7:00 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $19.34
Real-time Price: $20.40 info
Change: +$1.06 (+5%) info
Market Cap: $682.276M info
NVCT
Oct 26, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $20.05
Real-time Price: $20.40 info
Change: +$0.350 (+2%) info
Market Cap: $682.276M info
NVCT
Sep 24, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $21.70
Real-time Price: $20.40 info
Change: -$1.30 (-6%) info
Market Cap: $682.276M info